Hyman Charles D lowered its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 4.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 185,771 shares of the biopharmaceutical company’s stock after selling 8,556 shares during the quarter. Bristol-Myers Squibb accounts for 1.3% of Hyman Charles D’s portfolio, making the stock its 27th largest position. Hyman Charles D’s holdings in Bristol-Myers Squibb were worth $11,384,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently modified their holdings of BMY. Delphi Private Advisors LLC purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth $108,000. Atlantic Trust LLC purchased a new position in shares of Bristol-Myers Squibb during the 2nd quarter worth $111,000. Massey Quick Simon & CO. LLC boosted its stake in shares of Bristol-Myers Squibb by 523.5% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 1,492 shares during the last quarter. Horan Capital Advisors LLC. purchased a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth $122,000. Finally, Acrospire Investment Management LLC boosted its stake in shares of Bristol-Myers Squibb by 633.3% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,200 shares of the biopharmaceutical company’s stock worth $123,000 after acquiring an additional 1,900 shares during the last quarter. Institutional investors own 71.55% of the company’s stock.
Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $67.45 on Tuesday. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59. The stock has a market cap of $110,885.03, a price-to-earnings ratio of 22.57, a price-to-earnings-growth ratio of 2.08 and a beta of 0.98. Bristol-Myers Squibb Co has a fifty-two week low of $51.56 and a fifty-two week high of $70.05.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be issued a $0.40 dividend. The ex-dividend date is Thursday, April 5th. This represents a $1.60 dividend on an annualized basis and a yield of 2.37%. Bristol-Myers Squibb’s dividend payout ratio is currently 271.19%.
BMY has been the topic of several analyst reports. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Vetr cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 target price on the stock. in a research note on Thursday, December 28th. Morgan Stanley upgraded shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $51.56 to $78.00 in a research note on Thursday, February 15th. BMO Capital Markets restated a “sell” rating and set a $52.00 target price on shares of Bristol-Myers Squibb in a research note on Monday, January 22nd. Finally, Leerink Swann lifted their target price on shares of Bristol-Myers Squibb from $71.00 to $76.00 and gave the company a “positive” rating in a research note on Tuesday, February 6th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the company. Bristol-Myers Squibb has a consensus rating of “Hold” and an average price target of $66.30.
In related news, Director Theodore R. Samuels II purchased 4,000 shares of Bristol-Myers Squibb stock in a transaction on Friday, December 15th. The shares were bought at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the acquisition, the director now owns 22,000 shares in the company, valued at approximately $1,370,600. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.23% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Hyman Charles D Reduces Position in Bristol-Myers Squibb Co (BMY)” was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/03/13/hyman-charles-d-reduces-position-in-bristol-myers-squibb-co-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.